TearLab prices $35.1 mil public offering of common stock

Article

 

San Diego-TearLab Corp. announced the pricing of an underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $13.50 per share for gross proceeds of $35.1 million.

Net proceeds from the sale of the shares will be approximately $32.6 million.  TearLab has also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover overallotments.

TearLab plans to use the net proceeds from this offering for commercialization of its products, research and development, working capital, and other general corporate purposes. The offering is expected to close on or about July 30, subject to the satisfaction of customary closing conditions.

Recent Videos
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
EnVision Summit cofounder and program chair Dr Bonnie Henderson chats about collaborative eye care
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Bonnie An Henderson in an interview for the EnVision Summit
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
© 2025 MJH Life Sciences

All rights reserved.